Fragile X Syndrome Market, Global Outlook and Forecast 2022-2028

March 2022 | 63 pages | ID: F11CD417319CEN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Fragile X Syndrome in Global, including the following market information:

Global Fragile X Syndrome Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Fragile X Syndrome market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

ACT-01 Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Fragile X Syndrome include Aelis Farma SAS, Alcobra Ltd, AMO Pharma Limited, Confluence Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Marinus Pharmaceuticals, Inc., MI.TO. Technology S.r.L. and Neuren Pharmaceuticals Limited, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Fragile X Syndrome companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Fragile X Syndrome Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Fragile X Syndrome Market Segment Percentages, by Type, 2021 (%)

• ACT-01
• AMO-01
• ANAVEX-273
• AUT-00206
• Bryostatin-1
• Cannabidiol
• Others

Global Fragile X Syndrome Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Fragile X Syndrome Market Segment Percentages, by Application, 2021 (%)

• Clinic
• Hopital
• Research Center

Global Fragile X Syndrome Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Fragile X Syndrome Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Fragile X Syndrome revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Fragile X Syndrome revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Aelis Farma SAS
• Alcobra Ltd
• AMO Pharma Limited
• Confluence Pharmaceuticals LLC
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Marinus Pharmaceuticals, Inc.
• MI.TO. Technology S.r.L.
• Neuren Pharmaceuticals Limited
• Ovid Therapeutics Inc.
• Sage Therapeutics, Inc.
• Zynerba Pharmaceuticals, Inc.

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Fragile X Syndrome Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Fragile X Syndrome Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL FRAGILE X SYNDROME OVERALL MARKET SIZE

2.1 Global Fragile X Syndrome Market Size: 2021 VS 2028
2.2 Global Fragile X Syndrome Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Fragile X Syndrome Players in Global Market
3.2 Top Global Fragile X Syndrome Companies Ranked by Revenue
3.3 Global Fragile X Syndrome Revenue by Companies
3.4 Top 3 and Top 5 Fragile X Syndrome Companies in Global Market, by Revenue in 2021
3.5 Global Companies Fragile X Syndrome Product Type
3.6 Tier 1, Tier 2 and Tier 3 Fragile X Syndrome Players in Global Market
  3.6.1 List of Global Tier 1 Fragile X Syndrome Companies
  3.6.2 List of Global Tier 2 and Tier 3 Fragile X Syndrome Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Fragile X Syndrome Market Size Markets, 2021 & 2028
  4.1.2 ACT-01
  4.1.3 AMO-01
  4.1.4 ANAVEX-273
  4.1.5 AUT-00206
  4.1.6 Bryostatin-1
  4.1.7 Cannabidiol
  4.1.8 Others
4.2 By Type - Global Fragile X Syndrome Revenue & Forecasts
  4.2.1 By Type - Global Fragile X Syndrome Revenue, 2017-2022
  4.2.2 By Type - Global Fragile X Syndrome Revenue, 2023-2028
  4.2.3 By Type - Global Fragile X Syndrome Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Fragile X Syndrome Market Size, 2021 & 2028
  5.1.2 Clinic
  5.1.3 Hopital
  5.1.4 Research Center
5.2 By Application - Global Fragile X Syndrome Revenue & Forecasts
  5.2.1 By Application - Global Fragile X Syndrome Revenue, 2017-2022
  5.2.2 By Application - Global Fragile X Syndrome Revenue, 2023-2028
  5.2.3 By Application - Global Fragile X Syndrome Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Fragile X Syndrome Market Size, 2021 & 2028
6.2 By Region - Global Fragile X Syndrome Revenue & Forecasts
  6.2.1 By Region - Global Fragile X Syndrome Revenue, 2017-2022
  6.2.2 By Region - Global Fragile X Syndrome Revenue, 2023-2028
  6.2.3 By Region - Global Fragile X Syndrome Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Fragile X Syndrome Revenue, 2017-2028
  6.3.2 US Fragile X Syndrome Market Size, 2017-2028
  6.3.3 Canada Fragile X Syndrome Market Size, 2017-2028
  6.3.4 Mexico Fragile X Syndrome Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Fragile X Syndrome Revenue, 2017-2028
  6.4.2 Germany Fragile X Syndrome Market Size, 2017-2028
  6.4.3 France Fragile X Syndrome Market Size, 2017-2028
  6.4.4 U.K. Fragile X Syndrome Market Size, 2017-2028
  6.4.5 Italy Fragile X Syndrome Market Size, 2017-2028
  6.4.6 Russia Fragile X Syndrome Market Size, 2017-2028
  6.4.7 Nordic Countries Fragile X Syndrome Market Size, 2017-2028
  6.4.8 Benelux Fragile X Syndrome Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Fragile X Syndrome Revenue, 2017-2028
  6.5.2 China Fragile X Syndrome Market Size, 2017-2028
  6.5.3 Japan Fragile X Syndrome Market Size, 2017-2028
  6.5.4 South Korea Fragile X Syndrome Market Size, 2017-2028
  6.5.5 Southeast Asia Fragile X Syndrome Market Size, 2017-2028
  6.5.6 India Fragile X Syndrome Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Fragile X Syndrome Revenue, 2017-2028
  6.6.2 Brazil Fragile X Syndrome Market Size, 2017-2028
  6.6.3 Argentina Fragile X Syndrome Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Fragile X Syndrome Revenue, 2017-2028
  6.7.2 Turkey Fragile X Syndrome Market Size, 2017-2028
  6.7.3 Israel Fragile X Syndrome Market Size, 2017-2028
  6.7.4 Saudi Arabia Fragile X Syndrome Market Size, 2017-2028
  6.7.5 UAE Fragile X Syndrome Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Aelis Farma SAS
  7.1.1 Aelis Farma SAS Corporate Summary
  7.1.2 Aelis Farma SAS Business Overview
  7.1.3 Aelis Farma SAS Fragile X Syndrome Major Product Offerings
  7.1.4 Aelis Farma SAS Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.1.5 Aelis Farma SAS Key News
7.2 Alcobra Ltd
  7.2.1 Alcobra Ltd Corporate Summary
  7.2.2 Alcobra Ltd Business Overview
  7.2.3 Alcobra Ltd Fragile X Syndrome Major Product Offerings
  7.2.4 Alcobra Ltd Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.2.5 Alcobra Ltd Key News
7.3 AMO Pharma Limited
  7.3.1 AMO Pharma Limited Corporate Summary
  7.3.2 AMO Pharma Limited Business Overview
  7.3.3 AMO Pharma Limited Fragile X Syndrome Major Product Offerings
  7.3.4 AMO Pharma Limited Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.3.5 AMO Pharma Limited Key News
7.4 Confluence Pharmaceuticals LLC
  7.4.1 Confluence Pharmaceuticals LLC Corporate Summary
  7.4.2 Confluence Pharmaceuticals LLC Business Overview
  7.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Major Product Offerings
  7.4.4 Confluence Pharmaceuticals LLC Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.4.5 Confluence Pharmaceuticals LLC Key News
7.5 Eli Lilly and Company
  7.5.1 Eli Lilly and Company Corporate Summary
  7.5.2 Eli Lilly and Company Business Overview
  7.5.3 Eli Lilly and Company Fragile X Syndrome Major Product Offerings
  7.5.4 Eli Lilly and Company Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.5.5 Eli Lilly and Company Key News
7.6 F. Hoffmann-La Roche Ltd.
  7.6.1 F. Hoffmann-La Roche Ltd. Corporate Summary
  7.6.2 F. Hoffmann-La Roche Ltd. Business Overview
  7.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Major Product Offerings
  7.6.4 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.6.5 F. Hoffmann-La Roche Ltd. Key News
7.7 Marinus Pharmaceuticals, Inc.
  7.7.1 Marinus Pharmaceuticals, Inc. Corporate Summary
  7.7.2 Marinus Pharmaceuticals, Inc. Business Overview
  7.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Major Product Offerings
  7.7.4 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.7.5 Marinus Pharmaceuticals, Inc. Key News
7.8 MI.TO. Technology S.r.L.
  7.8.1 MI.TO. Technology S.r.L. Corporate Summary
  7.8.2 MI.TO. Technology S.r.L. Business Overview
  7.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Major Product Offerings
  7.8.4 MI.TO. Technology S.r.L. Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.8.5 MI.TO. Technology S.r.L. Key News
7.9 Neuren Pharmaceuticals Limited
  7.9.1 Neuren Pharmaceuticals Limited Corporate Summary
  7.9.2 Neuren Pharmaceuticals Limited Business Overview
  7.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Major Product Offerings
  7.9.4 Neuren Pharmaceuticals Limited Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.9.5 Neuren Pharmaceuticals Limited Key News
7.10 Ovid Therapeutics Inc.
  7.10.1 Ovid Therapeutics Inc. Corporate Summary
  7.10.2 Ovid Therapeutics Inc. Business Overview
  7.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Major Product Offerings
  7.10.4 Ovid Therapeutics Inc. Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.10.5 Ovid Therapeutics Inc. Key News
7.11 Sage Therapeutics, Inc.
  7.11.1 Sage Therapeutics, Inc. Corporate Summary
  7.11.2 Sage Therapeutics, Inc. Business Overview
  7.11.3 Sage Therapeutics, Inc. Fragile X Syndrome Major Product Offerings
  7.11.4 Sage Therapeutics, Inc. Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.11.5 Sage Therapeutics, Inc. Key News
7.12 Zynerba Pharmaceuticals, Inc.
  7.12.1 Zynerba Pharmaceuticals, Inc. Corporate Summary
  7.12.2 Zynerba Pharmaceuticals, Inc. Business Overview
  7.12.3 Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Major Product Offerings
  7.12.4 Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Revenue in Global Market (2017-2022)
  7.12.5 Zynerba Pharmaceuticals, Inc. Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Fragile X Syndrome Market Opportunities & Trends in Global Market
Table 2. Fragile X Syndrome Market Drivers in Global Market
Table 3. Fragile X Syndrome Market Restraints in Global Market
Table 4. Key Players of Fragile X Syndrome in Global Market
Table 5. Top Fragile X Syndrome Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Fragile X Syndrome Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Fragile X Syndrome Revenue Share by Companies, 2017-2022
Table 8. Global Companies Fragile X Syndrome Product Type
Table 9. List of Global Tier 1 Fragile X Syndrome Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Fragile X Syndrome Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Fragile X Syndrome Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Fragile X Syndrome Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Fragile X Syndrome Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Fragile X Syndrome Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Fragile X Syndrome Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Fragile X Syndrome Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Fragile X Syndrome Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Fragile X Syndrome Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Fragile X Syndrome Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Fragile X Syndrome Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Fragile X Syndrome Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Fragile X Syndrome Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Fragile X Syndrome Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Fragile X Syndrome Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Fragile X Syndrome Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Fragile X Syndrome Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Fragile X Syndrome Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Fragile X Syndrome Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Fragile X Syndrome Revenue, (US$, Mn), 2023-2028
Table 30. Aelis Farma SAS Corporate Summary
Table 31. Aelis Farma SAS Fragile X Syndrome Product Offerings
Table 32. Aelis Farma SAS Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 33. Alcobra Ltd Corporate Summary
Table 34. Alcobra Ltd Fragile X Syndrome Product Offerings
Table 35. Alcobra Ltd Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 36. AMO Pharma Limited Corporate Summary
Table 37. AMO Pharma Limited Fragile X Syndrome Product Offerings
Table 38. AMO Pharma Limited Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 39. Confluence Pharmaceuticals LLC Corporate Summary
Table 40. Confluence Pharmaceuticals LLC Fragile X Syndrome Product Offerings
Table 41. Confluence Pharmaceuticals LLC Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 42. Eli Lilly and Company Corporate Summary
Table 43. Eli Lilly and Company Fragile X Syndrome Product Offerings
Table 44. Eli Lilly and Company Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 45. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 46. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Product Offerings
Table 47. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 48. Marinus Pharmaceuticals, Inc. Corporate Summary
Table 49. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Product Offerings
Table 50. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 51. MI.TO. Technology S.r.L. Corporate Summary
Table 52. MI.TO. Technology S.r.L. Fragile X Syndrome Product Offerings
Table 53. MI.TO. Technology S.r.L. Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 54. Neuren Pharmaceuticals Limited Corporate Summary
Table 55. Neuren Pharmaceuticals Limited Fragile X Syndrome Product Offerings
Table 56. Neuren Pharmaceuticals Limited Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 57. Ovid Therapeutics Inc. Corporate Summary
Table 58. Ovid Therapeutics Inc. Fragile X Syndrome Product Offerings
Table 59. Ovid Therapeutics Inc. Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 60. Sage Therapeutics, Inc. Corporate Summary
Table 61. Sage Therapeutics, Inc. Fragile X Syndrome Product Offerings
Table 62. Sage Therapeutics, Inc. Fragile X Syndrome Revenue (US$, Mn), (2017-2022)
Table 63. Zynerba Pharmaceuticals, Inc. Corporate Summary
Table 64. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Product Offerings
Table 65. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Fragile X Syndrome Segment by Type in 2021
Figure 2. Fragile X Syndrome Segment by Application in 2021
Figure 3. Global Fragile X Syndrome Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Fragile X Syndrome Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Fragile X Syndrome Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Fragile X Syndrome Revenue in 2021
Figure 8. By Type - Global Fragile X Syndrome Revenue Market Share, 2017-2028
Figure 9. By Application - Global Fragile X Syndrome Revenue Market Share, 2017-2028
Figure 10. By Region - Global Fragile X Syndrome Revenue Market Share, 2017-2028
Figure 11. By Country - North America Fragile X Syndrome Revenue Market Share, 2017-2028
Figure 12. US Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Fragile X Syndrome Revenue Market Share, 2017-2028
Figure 16. Germany Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 17. France Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Fragile X Syndrome Revenue Market Share, 2017-2028
Figure 24. China Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 28. India Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Fragile X Syndrome Revenue Market Share, 2017-2028
Figure 30. Brazil Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Fragile X Syndrome Revenue Market Share, 2017-2028
Figure 33. Turkey Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Fragile X Syndrome Revenue, (US$, Mn), 2017-2028
Figure 37. Aelis Farma SAS Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Alcobra Ltd Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AMO Pharma Limited Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Confluence Pharmaceuticals LLC Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Eli Lilly and Company Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. MI.TO. Technology S.r.L. Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Neuren Pharmaceuticals Limited Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Ovid Therapeutics Inc. Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Sage Therapeutics, Inc. Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Revenue Year Over Year Growth (US$, Mn) & (2017-2022)